AB 2000: Drug formularies.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2026-04-16
Current Status:
In Progress
(2026-05-14: Joint Rule 62(a), file notice suspended. (Page 5030.))
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies to meet certain criteria for its formularies and the placement of drugs on formularies.
This bill would prohibit a health care service plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies from making changes to a formulary during a plan or policy year, except in specified circumstances. If a plan or insurer implements a formulary change requiring an enrollee or insured to change to a different drug in the same drug class during the plan year, the bill would authorize the individual to remain on the previously covered drug for the rest of the plan year if the drug was previously approved for coverage for the individuals medical condition, is appropriately prescribed, and is considered safe and effective for treating that condition, and would require the plan or insurer to notify the individual and their provider no less than 90 days before the change is implemented. The bill would require a plan or insurer, or its pharmacy benefit manager, to report to the appropriate department any changes made to a formulary during a plan or policy year within 30 days of the change being made. The bill would authorize the departments to impose investigate and take enforcement action against a plan or insurer for noncompliance with the above-described requirements and to impose, after notice and the opportunity for a hearing, administrative penalties, as specified, for a violation of these provisions. The bill would authorize the departments to conduct audits related to these provisions. Because a willful violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
Existing law requires a health care service plan that provides prescription drug benefits to maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary nonformulary prescription drug.
This bill would define expeditious process for the above-described purpose to require a plan to approve authorization within 72 hours for nonurgent requests, or within 24 hours if exigent circumstances exist, of a request for approval of a drug prescription. If the plan fails to meet those requirements, the bill would authorize an enrollee to request, and would require the plan to provide, 90 days of transitional coverage to the enrollee for the previously covered drug. The bill would require the Department of Managed Health Care to utilize existing data and its existing authority to collect data from plans and annually publish on its internet website and submit to the Legislature an aggregated report on information related to requests for approval of a nonformulary drug as described above.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies to meet certain criteria for its formularies and the placement of drugs on formularies.
This bill would prohibit a health care service plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies from making changes to a formulary during a plan or policy year, except in specified circumstances. The bill would require a plan or insurer, or its pharmacy benefit manager, to report to the appropriate department any changes made to a formulary during a plan or policy year within 30 days of the change being made. The bill would authorize the departments to impose administrative penalties, as specified, for a violation of these provisions. The bill would authorize the departments to conduct audits related to these provisions. Because a willful violation of the bills provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law requires specified services and drugs to be covered by the various plans. Existing law prohibits specified health care service plan contracts that cover prescription drug benefits from limiting or excluding coverage for a drug for an enrollee under specified conditions, including if the drug previously had been approved for coverage by the plan for a medical condition of the enrollee. Existing law specifies that these provisions do not preclude the prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee.This bill would make technical, nonsubstantive changes to these provisions. The bill would state the intent of the Legislature to protect patients from mid-year health care service plan formulary changes that disrupt care and restrict access to medically necessary medications.Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the acts requirements a crime. Existing law requires specified services and drugs to be covered by the various plans. Existing law prohibits specified health care service plan contracts that cover prescription drug benefits from limiting or excluding coverage for a drug for an enrollee under specified conditions, including if the drug previously had been approved for coverage by the plan for a medical condition of the enrollee. Existing law specifies that these provisions do not preclude the prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee.
This bill would make technical, nonsubstantive changes to these provisions. The bill would state the intent of the Legislature to protect patients from mid-year health care service plan formulary changes that disrupt care and restrict access to medically necessary medications.
(a)A Except as described in subdivision (b), a health care service plan that provides prescription drug benefits and maintains one or more drug formularies shall not make changes to a formulary during a plan year, including removing a drug from a formulary, moving a drug to a higher cost tier, or imposing new utilization management requirements on a drug. moving a drug to a higher cost tier.
(b)Notwithstanding subdivision (a), a health care service plan may make changes to a formulary for any of the following reasons:
(1)To add a newly approved drug. If a generic drug is newly approved, the cost sharing for the newly approved generic drug shall be lower than the brand name drug, but brand name drug coverage shall not be removed until the end of the plan year. an additional drug to the formulary.
(2)(A)To replace a covered drug on the formulary with another drug in the same drug class. The enrollees cost sharing for the newly covered drug during the plan year shall be the same as or lower than the cost-sharing amount for the previously covered drug.
(B)To replace a covered brand name drug on the formulary with a generic drug of the same drug class. The enrollees cost sharing for the newly covered drug during the plan year shall be lower than the cost-sharing amount for the previously covered drug.
(C)To replace a covered brand name drug on the formulary with a generic drug of the same drug. The enrollees cost sharing for the newly covered drug during the plan year shall be lower than the cost-sharing amount for the previously covered drug.
(3)To add a biosimilar or interchangeable biologic product that is the same or similar to a previously covered drug or reference product if the net cost to the plan and the amount of the enrollees cost sharing is the same as or lower than the net cost to the plan and the cost-sharing amount for the previously covered drug or reference product.
(2)(4)To remove a drug due to safety concerns from the United States Food and Drug Administration.
(3)(5)To move a specified drug to a lower formulary tier or otherwise modify its formulary placement in a manner that reduces enrollee cost sharing.
(4)(6)To remove utilization management or prior authorization requirements for a covered drug.
(c)(1)If the plan implements a formulary change requiring an enrollee to change to a different drug in the same drug class during the plan year, the enrollee may remain on the previously covered drug for the rest of the plan year if all of the following conditions are met:
(A)The drug was previously approved for coverage by the plan for a medical condition of the enrollee.
(B)The drug is appropriately prescribed to the enrollee.
(C)The drug is considered safe and effective for treating the enrollees medical condition.
(2)If the plan requires an enrollee to change to a different drug as described in paragraph (1), the plan shall notify the enrollee and their prescribing provider no less than 90 days before the formulary change is implemented. The notification shall include information about existing requirements for continuity of coverage for previously covered drugs as described in Section 1367.22.
(3)This subdivision does not prohibit the prescribing provider from prescribing a different drug that is covered by the plan that is medically appropriate for the enrollee.
(4)This subdivision does not prohibit the prescribing provider from prescribing a generic drug substitution as described in Section 4073 of the Business and Professions Code.
(c)(d)(1)A health care service plan or its pharmacy benefit manager shall report to the department any changes made to a formulary during a plan year within 30 days of the change being made.
(2)A health care service plan shall authorize appeals for coverage denials based on formulary changes through its existing internal and external appeals processes.
(d)(1)The department may impose an administrative penalty for a violation of this section of not less than five hundred dollars ($500) per 1,000 enrollees and up to five thousand dollars ($5,000) per 1,000 enrollees.(e)(1)(A)The director may investigate and take enforcement action against a plan for noncompliance with the requirements of this section.
(B)The director may, by order, assess administrative penalties of not less than five hundred dollars ($500) per 1,000 enrollees and up to five thousand dollars ($5,000) per 1,000 enrollees, subject to appropriate notice of, and the opportunity for, a hearing in accordance with Section 1397.
(2)When assessing administrative penalties against a health care service plan pursuant to paragraph (1), the department shall determine the appropriate penalty amount for each violation based on one or more factors as applicable, including the factors outlined in subdivision (d) of Section 1386.
(3)The plan may provide to the director, and the director may consider for the purposes of the determination described in paragraph (2), information regarding the plans overall compliance with the requirements of this section.
(3)(4)Beginning January 1, 2030, and every five years thereafter, the penalty amounts specified in paragraph (1) shall be adjusted based on the average rate of change in premium rates for the individual and small group markets, and weighted by enrollment, since the previous adjustment.
(4)(5)Penalties levied by the department on a plan pursuant to this subdivision shall be paid by the plan and shall not be paid by the provider, subscriber, or enrollee.
(e)(f)The department may conduct audits that relate to this section and are not based on an enrollees complaint.
(f)(g)For purposes of this section, formulary has the same meaning as defined in Section 1367.205.
SEC. 2.Section 1367.24 of the Health and Safety Code is amended to read:1367.24.(a)Every (1)A health care service plan that provides prescription drug benefits shall maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary nonformulary prescription drug. On or before July 1, 1999, every a health care service plan that provides prescription drug benefits shall file with the department a description of its process, including timelines, for responding to authorization requests for nonformulary drugs. Any changes to this process shall be filed with the department pursuant to Section 1352. Each A plan shall provide a written description of its most current process, including timelines, to its prescribing providers. For purposes of this section, a prescribing provider shall include includes a provider authorized to write a prescription, pursuant to subdivision (a) of Section 4040 of the Business and Professions Code, to treat a medical condition of an enrollee.
(2)For the purposes of this section, expeditious process means the plan shall approve authorization within 72 hours for nonurgent requests, or within 24 hours if exigent circumstances exist, upon receipt of a request for approval of a drug prescription as described in paragraph (1).
(3)If the plan fails to meet the requirements described in paragraph (2), an enrollee may request, and the plan shall provide, 90 days of transitional coverage to the enrollee for the previously covered drug.
(b)Any A plan that disapproves a request made pursuant to subdivision (a) by a prescribing provider to obtain authorization for a nonformulary drug shall provide the reasons for the disapproval in a notice provided to the enrollee. The notice shall indicate that the enrollee may file a grievance with the plan if the enrollee objects to the disapproval, including any alternative drug or treatment offered by the plan. The notice shall comply with subdivision (b) of Section 1368.02. Any health plan that is required to maintain an external exception request review process pursuant to subdivision (k) shall indicate in the notice required under this subdivision that the enrollee may file a grievance seeking an external exception request review.
(c)The process described in subdivision (a) by which prescribing providers may obtain authorization for medically necessary nonformulary drugs shall not apply to a nonformulary drug that has been prescribed for an enrollee in conformance with the provisions of Section 1367.22.
(d)The process described in subdivision (a) by which enrollees may obtain medically necessary nonformulary drugs, including specified timelines for responding to prescribing provider authorization requests, shall be described in evidence of coverage and disclosure forms, as required by subdivisions (a) and (b) of Section 1363, issued on or after July 1, 1999.
(e)Every A health care service plan that provides prescription drug benefits shall maintain, as part of its books and records under Section 1381, all of the following information, which shall be made available to the director upon request:
(1)The complete drug formulary or formularies of the plan, if the plan maintains a formulary, including a list of the prescription drugs on the formulary of the plan by major therapeutic category with an indication of whether any drugs are preferred over other drugs.
(2)Records developed by the pharmacy and therapeutic committee of the plan, or by others responsible for developing, modifying, and overseeing formularies, including medical groups, individual practice associations, and contracting pharmaceutical benefit management companies, used to guide the drugs prescribed for the enrollees of the plan, that fully describe the reasoning behind formulary decisions.
(3)Any plan arrangements with prescribing providers, medical groups, individual practice associations, pharmacists, contracting pharmaceutical benefit management companies, or other entities that are associated with activities of the plan to encourage formulary compliance or otherwise manage prescription drug benefits.
(f)If a plan provides prescription drug benefits, the department shall, as part of its periodic onsite medical survey of each plan undertaken pursuant to Section 1380, review the performance of the plan in providing those benefits, including, but not limited to, a review of the procedures and information maintained pursuant to this section, and describe the performance of the plan as part of its report issued pursuant to Section 1380.
(g)The director shall not publicly disclose any information reviewed pursuant to this section that is determined by the director to be confidential pursuant to state law.
(h)For purposes of this section, authorization means approval by the health care service plan to provide payment for the prescription drug.
(i)Nonformulary prescription drugs shall include any drug for which an enrollees copayment or out-of-pocket costs are different than the copayment for a formulary prescription drug, except as otherwise provided by law or regulation or in cases in which the drug has been excluded in the plan contract pursuant to Section 1342.7.
(j)Nothing in this section shall be construed to This section does not restrict or impair the application of any other provision of this chapter, including, but not limited to, Section 1367, which includes among its requirements that a health care service plan furnish services in a manner providing continuity of care and demonstrate that medical decisions are rendered by qualified medical providers unhindered by fiscal and administrative management.
(k)For any an individual, small group, or large health plan contracts, contract, a health care service plans process described in subdivision (a) shall comply with the request for exception and external exception request review processes described in subdivision (c) of Section 156.122 of Title 45 of the Code of Federal Regulations. This subdivision shall does not apply to Medi-Cal managed care health care service plan contracts as described in subdivision (l).
(l)Medi-Cal managed care health care service plan contract means any an entity that enters into a contract with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
(m)Nothing in this section shall be construed to This section does not affect an enrollees or subscribers eligibility to submit a grievance to the department for review under Section 1368 or to apply to the department for an independent medical review under Section 1370.4, or Article 5.55 (commencing with Section 1374.30) of this chapter.
(n)(1)The department shall utilize existing data and the authority granted pursuant to this chapter to collect data from plans and annually publish on its internet website an aggregated report on all of the following:
(A)The number of requests made by an enrollee pursuant to subdivision (a).
(B)The number of requests made by an enrollee pursuant to subdivision (a) that were approved.
(C)The number of requests made by an enrollee pursuant to subdivision (a) that were denied.
(D)The number of requests made by an enrollee pursuant to subdivision (a) that were appealed and the outcome of those appeals.
(E)The number of requests made by an enrollee pursuant to subdivision (a) that resulted in an independent medical review pursuant to Section 1374.30.
(2)(A)The department shall annually submit the report described in paragraph (1) to the Legislature.
(B)A report submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
SEC. 2.SEC. 3.Section 10123.2041 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2041.(a)A Except as described in subdivision (b), a health insurer that provides prescription drug benefits and maintains one or more drug formularies shall not make changes to a formulary during a policy year, including removing a drug from a formulary, moving a drug to a higher cost tier, or imposing new utilization management requirements on a drug. moving a drug to a higher cost tier.
(b)Notwithstanding subdivision (a), a health insurer may make changes to a formulary for any of the following reasons:
(1)To add a newly approved drug. If a generic drug is newly approved, the cost sharing for the newly approved generic drug shall be lower than the brand name drug, but brand name drug coverage shall not be removed until the end of the policy year. an additional drug to the formulary.
(2)(A)To replace a covered drug on the formulary with another drug in the same drug class. The insureds cost sharing for the newly covered drug during the plan year shall be the same as or lower than the cost-sharing amount for the previously covered drug.
(B)To replace a covered brand name drug on the formulary with a generic drug of the same drug class. The insureds cost sharing for the newly covered drug during the plan year shall be lower than the cost-sharing amount for the previously covered drug.
(C)To replace a covered brand name drug on the formulary with a generic drug of the same drug. The insureds cost sharing for the newly covered drug during the plan year shall be lower than the cost-sharing amount for the previously covered drug.
(3)To add a biosimilar or interchangeable biologic product that is the same or similar to a previously covered drug or reference product if the net cost to the plan and the amount of the insureds cost sharing is the same as or lower than the net cost to the plan and the cost-sharing amount for the previously covered drug or reference product.
(2)(4)To remove a drug due to safety concerns from the United States Food and Drug Administration.
(3)(5)To move a specified drug to a lower formulary tier or otherwise modify its formulary placement in a manner that reduces insured cost sharing.
(4)(6)To remove utilization management or prior authorization requirements for a covered drug.
(c)(1)If the insurer implements a formulary change requiring an insured to change to a different drug in the same drug class during the policy year, the insured may remain on the previously covered drug for the rest of the policy year if all of the following conditions are met:
(A)The drug was previously approved for coverage by the insurer for a medical condition of the insured.
(B)The drug is appropriately prescribed to the insured.
(C)The drug is considered safe and effective for treating the insureds medical condition.
(2)If the insurer requires an insured to change to a different drug as described in paragraph (1), the insurer shall notify the insured and their prescribing provider no less than 90 days before the formulary change is implemented. The notification shall include information about existing requirements for continuity of coverage for previously covered drugs.
(3)This subdivision does not prohibit the prescribing provider from prescribing a different drug that is covered by the insurer that is medically appropriate for the insured.
(4)This subdivision does not prohibit the prescribing provider from prescribing a generic drug substitution as described in Section 4073 of the Business and Professions Code.
(c)(d)(1)A health insurer or its pharmacy benefit manager shall report to the department any changes made to a formulary during a policy year within 30 days of the change being made.
(2)A health insurer shall authorize appeals for coverage denials based on formulary changes through its existing internal and external appeals processes.
(d)(1)The department may impose an administrative penalty for a violation of this section of not less than five hundred dollars ($500) per 1,000 insureds and up to five thousand dollars ($5,000) per 1,000 insureds.(e)(1)(A)The commissioner may investigate and take enforcement action against an insurer for noncompliance with the requirements of this section.
(B)The commissioner may, by order, assess administrative penalties of not less than five hundred dollars ($500) per 1,000 insureds and up to five thousand dollars ($5,000) per 1,000 insureds, subject to appropriate notice of, and the opportunity for, a hearing in accordance with the Administrative Procedure Act (Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code), and the commissioner shall have all of the powers granted under the act.
(2)When assessing administrative penalties against a health insurer pursuant to paragraph (1), the department shall determine the appropriate penalty amount for each violation based on one or more factors as applicable, including all of the following factors:
(A)The nature, scope, and gravity of the violation.
(B)The good or bad faith of the insurer.
(C)The insurers history of violations.
(D)The willfulness of the violation.
(E)The nature and extent to which the insurer cooperated with the departments investigation.
(F)The nature and extent to which the insurer aggravated or mitigated any injury or damage caused by the violation.
(G)The nature and extent to which the insurer has taken corrective action to ensure the violation will not recur.
(H)The financial status of the insurer, including reserves, financial solvency, revenues in excess of expenditures and other factors relating to the financial status of the domestic corporation and any parent company, subsidiary, affiliate, or other financially connected entity, if any.
(I)The financial cost of the formulary changes to insureds, including whether the penalty is commensurate with or exceeds the avoided cost based on the number of insureds estimated to be affected.
(J)Whether the violation is an isolated incident.
(3)The insurer may provide to the commissioner, and the commissioner may consider for the purposes of the determination described in paragraph (2), information regarding the insurers overall compliance with the requirements of this section.
(3)(4)In addition to paragraph (2), the amount of the penalty determined to be appropriate pursuant to paragraphs (2) and (3), the amount of the penalty shall also take into account one or more of the following, as applicable:
(A)The number of insureds estimated to be affected.
(B)The frequency of the violation based on the number of days for a continuous violation or the estimated number of incidents with potential harm to insureds.
(C)The severity of the potential harm in terms of loss of life, loss of health, or financial harm to the insured.
(D)The amount of the penalty necessary to deter similar violations in the future.
(4)(5)Beginning January 1, 2030, and every five years thereafter, the penalty amounts specified in paragraph (1) shall be adjusted based on the average rate of change in premium rates for the individual and small group markets, and weighted by enrollment, since the previous adjustment.
(5)(6)Penalties levied by the department on an insurer pursuant to this subdivision shall be paid by the insurer and shall not be paid by the provider, subscriber, or insured.
(e)(f)The department may conduct audits that relate to this section and are not based on an insureds complaint.
(f)(g)For purposes of this section, formulary has the same meaning as defined in Section 10123.192.
SEC. 3.SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan that provides prescription drug benefits and maintains one or more drug formularies shall not make changes to a formulary during a plan year, including removing a drug from a formulary, moving a drug to a higher cost tier, or imposing new utilization management requirements on a drug.
(b)Notwithstanding subdivision (a), a health care service plan may make changes to a formulary for any of the following reasons:
(1)To add a newly approved drug. If a generic drug is newly approved, the cost sharing for the newly approved generic drug shall be lower than the brand name drug, but brand name drug coverage shall not be removed until the end of the plan year.
(2)To remove a drug due to safety concerns from the United States Food and Drug Administration.
(3)To move a specified drug to a lower formulary tier or otherwise modify its formulary placement in a manner that reduces enrollee cost sharing.
(4)To remove utilization management or prior authorization requirements for a covered drug.
(c)(1)A health care service plan or its pharmacy benefit manager shall report to the department any changes made to a formulary during a plan year within 30 days of the change being made.
(2)A health care service plan shall authorize appeals for coverage denials based on formulary changes through its existing internal and external appeals processes.
(d)(1)The department may impose an administrative penalty for a violation of this section of not less than five hundred dollars ($500) per 1,000 enrollees and up to five thousand dollars ($5,000) per 1,000 enrollees.
(2)When assessing administrative penalties against a health care service plan pursuant to paragraph (1), the department shall determine the appropriate penalty amount for each violation based on one or more factors as applicable, including the factors outlined in subdivision (d) of Section 1386.
(3)Beginning January 1, 2030, and every five years thereafter, the penalty amounts specified in paragraph (1) shall be adjusted based on the average rate of change in premium rates for the individual and small group markets, and weighted by enrollment, since the previous adjustment.
(4)Penalties levied by the department on a plan pursuant to this subdivision shall be paid by the plan and shall not be paid by the provider, subscriber, or enrollee.
(e)The department may conduct audits that relate to this section and are not based on an enrollees complaint.
(f)For purposes of this section, formulary has the same meaning as in Section 1367.205.
SEC. 2.Section 10123.2041 is added to the Insurance Code, immediately following Section 10123.204, to read:10123.2041.(a)A health insurer that provides prescription drug benefits and maintains one or more drug formularies shall not make changes to a formulary during a policy year, including removing a drug from a formulary, moving a drug to a higher cost tier, or imposing new utilization management requirements on a drug.
(b)Notwithstanding subdivision (a), a health insurer may make changes to a formulary for any of the following reasons:
(1)To add a newly approved drug. If a generic drug is newly approved, the cost sharing for the newly approved generic drug shall be lower than the brand name drug, but brand name drug coverage shall not be removed until the end of the policy year.
(2)To remove a drug due to safety concerns from the United States Food and Drug Administration.
(3)To move a specified drug to a lower formulary tier or otherwise modify its formulary placement in a manner that reduces insured cost sharing.
(4)To remove utilization management or prior authorization requirements for a covered drug.
(c)(1)A health insurer or its pharmacy benefit manager shall report to the department any changes made to a formulary during a policy year within 30 days of the change being made.
(2)A health insurer shall authorize appeals for coverage denials based on formulary changes through its existing internal and external appeals processes.
(d)(1)The department may impose an administrative penalty for a violation of this section of not less than five hundred dollars ($500) per 1,000 insureds and up to five thousand dollars ($5,000) per 1,000 insureds.
(2)When assessing administrative penalties against a health insurer pursuant to paragraph (1), the department shall determine the appropriate penalty amount for each violation based on one or more factors as applicable, including all of the following factors:
(A)The nature, scope, and gravity of the violation.
(B)The good or bad faith of the insurer.
(C)The insurers history of violations.
(D)The willfulness of the violation.
(E)The nature and extent to which the insurer cooperated with the departments investigation.
(F)The nature and extent to which the insurer aggravated or mitigated any injury or damage caused by the violation.
(G)The nature and extent to which the insurer has taken corrective action to ensure the violation will not recur.
(H)The financial status of the insurer, including reserves, financial solvency, revenues in excess of expenditures and other factors relating to the financial status of the domestic corporation and any parent company, subsidiary, affiliate, or other financially connected entity, if any.
(I)The financial cost of the formulary changes to insureds, including whether the penalty is commensurate with or exceeds the avoided cost based on the number of insureds estimated to be affected.
(J)Whether the violation is an isolated incident.
(3)In addition to paragraph (2), the amount of the penalty shall also take into account one or more of the following, as applicable:
(A)The number of insureds estimated to be affected.
(B)The frequency of the violation based on the number of days for a continuous violation or the estimated number of incidents with potential harm to insureds.
(C)The severity of the potential harm in terms of loss of life, loss of health, or financial harm to the insured.
(D)The amount of the penalty necessary to deter similar violations in the future.
(4)Beginning January 1, 2030, and every five years thereafter, the penalty amounts specified in paragraph (1) shall be adjusted based on the average rate of change in premium rates for the individual and small group markets, and weighted by enrollment, since the previous adjustment.
(5)Penalties levied by the department on an insurer pursuant to this subdivision shall be paid by the insurer and shall not be paid by the provider, subscriber, or insured.
(e)The department may conduct audits that relate to this section and are not based on an insureds complaint.
(f)For purposes of this section, formulary has the same meaning as in Section 10123.192.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SECTION 1.It is the intent of the Legislature to protect patients from mid-year health care service plan formulary changes that disrupt care and restrict access to medically necessary medications. SEC. 2.Section 1367.22 of the Health and Safety Code is amended to read:1367.22.(a)A health care service plan contract, issued, amended, or renewed on or after July 1, 1999, that covers prescription drug benefits shall not limit or exclude coverage for a drug for an enrollee if the drug previously had been approved for coverage by the plan for a medical condition of the enrollee and the plans prescribing provider continues to prescribe the drug for the medical condition, provided that the drug is appropriately prescribed and is considered safe and effective for treating the enrollees medical condition. This section does not preclude the prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee. This section does not prohibit generic drug substitutions as authorized by Section 4073 of the Business and Professions Code. For purposes of this section, a prescribing provider includes a provider authorized to write a prescription, pursuant to subdivision (a) of Section 4059 of the Business and Professions Code, to treat a medical condition of an enrollee.(b)This section does not apply to coverage for any drug that is prescribed for a use that is different from the use for which that drug has been approved for marketing by the federal Food and Drug Administration. Coverage for different-use drugs is subject to Section 1367.21.(c)This section does not restrict or impair the application of any other provision of this chapter, including, but not limited to, Section 1367, which includes among its requirements that plans furnish services in a manner providing continuity of care and demonstrate that medical decisions are rendered by qualified medical providers unhindered by fiscal and administrative management.(d)This section does not prohibit a health care service plan from charging a subscriber or enrollee a copayment or a deductible for prescription drug benefits or from setting forth, by contract, limitations on maximum coverage of prescription drug benefits, provided that the copayments, deductibles, or limitations are reported to, and held unobjectionable by, the director and set forth to the subscriber or enrollee pursuant to the disclosure provisions of Section 1363.It is the intent of the Legislature to protect patients from mid-year health care service plan formulary changes that disrupt care and restrict access to medically necessary medications.
SEC. 2.Section 1367.22 of the Health and Safety Code is amended to read:1367.22.(a)A health care service plan contract, issued, amended, or renewed on or after July 1, 1999, that covers prescription drug benefits shall not limit or exclude coverage for a drug for an enrollee if the drug previously had been approved for coverage by the plan for a medical condition of the enrollee and the plans prescribing provider continues to prescribe the drug for the medical condition, provided that the drug is appropriately prescribed and is considered safe and effective for treating the enrollees medical condition. Nothing in this section shall This section does not preclude the prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee, nor shall anything in this section be construed to enrollee. This section does not prohibit generic drug substitutions as authorized by Section 4073 of the Business and Professions Code. For purposes of this section, a prescribing provider shall include includes a provider authorized to write a prescription, pursuant to subdivision (a) of Section 4059 of the Business and Professions Code, to treat a medical condition of an enrollee.
(b)This section does not apply to coverage for any drug that is prescribed for a use that is different from the use for which that drug has been approved for marketing by the federal Food and Drug Administration. Coverage for different-use drugs is subject to Section 1367.21.
(c)This section shall not be construed to does not restrict or impair the application of any other provision of this chapter, including, but not limited to, Section 1367, which includes among its requirements that plans furnish services in a manner providing continuity of care and demonstrate that medical decisions are rendered by qualified medical providers unhindered by fiscal and administrative management.
(d)This section does not prohibit a health care service plan from charging a subscriber or enrollee a copayment or a deductible for prescription drug benefits or from setting forth, by contract, limitations on maximum coverage of prescription drug benefits, provided that the copayments, deductibles, or limitations are reported to, and held unobjectionable by, the director and set forth to the subscriber or enrollee pursuant to the disclosure provisions of Section 1363.
|
Date
|
Status
|
|---|---|
| May 14, 2026 | Joint Rule 62(a), file notice suspended. (Page 5030.) |
| May 14, 2026 | In committee: Held under submission. |
| May 14, 2026 | Joint Rule 62(a), file notice suspended. |
| May 13, 2026 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 20, 2026 | Re-referred to Com. on APPR. |
| Apr 16, 2026 | Read second time and amended. |
| Apr 15, 2026 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 14). |
| Mar 10, 2026 | Re-referred to Com. on HEALTH. |
| Mar 9, 2026 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 9, 2026 | Referred to Com. on HEALTH. |
| Feb 18, 2026 | From printer. May be heard in committee March 20. |
| Feb 17, 2026 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Apr 14, 2026 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Association for Clinical Oncology | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| California Academy Of Family Physicians | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Chronic Care Coalition | ** Support | |
| California Life Sciences Association | ** Support | |
| Crohn’s and Colitis Foundation | ** Support | |
| Health Access | ** Support | |
| National Health Law Program | ** Support | |
| Pharmaceutical Care Management Association | ** Against |
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 2000
Author:(Aguiar-Curry) – As Amended Ver:April 16, 2026
Policy Committee: | Health | Vote: | 16 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill prohibits a health plan or health insurer (collectively, health plan) that provides prescription drug benefits and maintains a drug formulary from making changes to a formulary during a plan or policy year, except as specified.
Specifically, this bill:
- Prohibits a health plan from making changes to a formulary during a plan year, including removing a drug from a formulary, moving a drug to a higher cost tier, or imposing new utilization management requirements on a drug.
- Provides exemptions to item (1), above, for any of the following reasons:
- To replace a covered drug on the formulary with another drug in the same drug class. Requires the enrollee’s cost sharing for the newly covered drug during the plan year to be the same as or lower than the cost-sharing amount for the previously covered drug.
- To replace a covered brand name drug on the formulary with a generic of the same drug or drug class; in which case the enrollee’s cost sharing for the newly covered drug during the plan year must be lower than the cost-sharing amount for the previously covered drug.
- To add a biosimilar or interchangeable biologic product that is the same or similar to a previously covered drug or reference product if the net cost to the plan and the amount of the enrollee’s cost sharing is the same as or lower than the net cost to the plan and the cost-sharing amount for the previously covered drug or reference product.
- To add an additional drug.
- To remove a drug due to safety concerns from the U.S. Food and Drug Administration.
- To move a specified drug to a lower formulary tier or otherwise modify its formulary placement in a manner that reduces enrollee cost sharing.
- To remove utilization management or prior authorization requirements for a covered drug.
- To replace a covered drug on the formulary with another drug in the same drug class. Requires the enrollee’s cost sharing for the newly covered drug during the plan year to be the same as or lower than the cost-sharing amount for the previously covered drug.
- Requires a health plan to allow an enrollee to remain on a drug for the rest of the plan year if the health plan implements a formulary change requiring an enrollee to change to a different drug in the same drug class, if specified conditions are met.
- Requires a health plan, insurer, or their pharmacy benefit manager (PBM) to report any changes made to a formulary during a plan year to the Department of Managed Health Care (DMHC) or California Department of Insurance (CDI) within 30 days of making the change.
- Requires a health plan or insurer to authorize appeals for coverage denials based on formulary changes through its existing internal and external appeals processes.
- Allows DMHC and CDI to impose an administrative penalty for a violation of $500 to $5,000 per 1,000 enrollees.
- Requires, beginning January 1, 2030, and every five years thereafter, the penalty amounts to be adjusted according to specified parameters.
- Requires penalties levied under this bill to be paid by the plan and not by the provider, subscriber, or enrollee.
- Allows DMHC and CDI to conduct audits that relate to this bill and are not based on an enrollee’s complaint.
- Requires DMHC and CDI to each use existing data and to collect data from health plans to prepare a report on authorizations for providers to prescribe medically necessary non-formulary prescription drugs, as specified, and annually publish the report on its website and submit that report to the Legislature.
FISCAL EFFECT:
- DMHC anticipates ongoing costs of up to $6.5 million, based on an increase in consumer complaints to DMHC’s Help Center, and protracted litigation due to the penalty structure of this bill (Managed Care Fund).
- CDI estimates costs of $10,000 in fiscal year (FY) 2026-27, $22,000 in FY 2027-28, and $19,000 in FY 2028-29 and ongoing (Insurance Fund).
- The California Public Employees Retirement System (CalPERS) estimates costs in the range of $0 to $7.7 million a year (General Fund). CalPERS explains that the range of cost from year to year depends on when cost-effective biosimilars or generics enter the market, particularly if there are alternatives to reference products with high costs and utilization amongst CalPERS members. This bill allows the addition of biosimilar or generic drugs but does not allow replacement of a reference product if the reference product is more costly, which means CalPERS would need to cover the reference product for the remainder of the year.
The Legislative Analyst’s Office recently warned of General Fund structural deficits of around $35 billion per year in the 2027-28 fiscal year and ongoing.
COMMENTS:
- Purpose. This bill is sponsored by California Academy of Family Physicians and the Crohn’s and Colitis Foundation. According to the author:
[This bill] prohibits health plans and PBMs from changing prescription drug coverage midyear, protecting patients from unexpected costs and treatment disruptions. It ensures Californians may continue needed medications, especially for chronic or serious conditions, without interruption. The bill also brings greater clarity and predictability to coverage, helping patients plan and budget for care. By safeguarding access to essential medications, [this bill] supports continuity of treatment, reduces administrative burdens on providers, and strengthens patient protections.
- Background. A formulary is a list of drugs a health plan or PBM has approved for coverage. Formularies are a tool used by plans to adapt to the evolving landscape of pharmacy products. With the rise of high-cost and specialty drugs, formulary management can be leveraged as a strategy to manage costs for the plan and enrollee while optimizing enrollee access to a range of prescription drugs.
Prescription drug costs have increased more rapidly than overall medical expenses and health plan premiums. In California, total prescription drug costs increased by 9.5% in 2024, whereas total medical expenses increased by 6.9% and health plan premiums increased by 8% from 2023 to 2024. Specialty drugs and brand name drugs are primary drivers of the increase in total prescription drug-cost spending. Brand name drugs account for only 9.4% of all prescriptions dispensed but accounted for 25.2% of total annual spending on prescription drugs. In contrast, generic drugs accounted for 88.8% of all prescriptions but only 11.8% of the total annual spending on prescription drugs. According to DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2024 than in 2023. Since 2017, total prescription drug costs paid by health plans increased by $6.2 billion or 72%.
While enrollees choose a plan for the plan year, changes in what is covered, new prescription drugs and approved uses, and more can happen at any time of the year. Health plans and PBMs negotiate their drug contracts and formularies throughout the year, not only at the beginning of the plan year. Although some formulary changes may be disruptive for patients and providers, many of these result from a more affordable drug becoming available, a different use for a drug, or a new generic or biosimilar coming to market. To allow plans to maintain formulary flexibility while ensuring patient continuity of care, existing law prohibits health plans from limiting or excluding coverage for a drug for an enrollee if the drug previously had been approved for coverage by the plan for their medical condition. Existing law also requires health plans to maintain a process for providers to request authorization to prescribe a medically necessary prescription drug that isn’t on their formulary.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 14, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 2000
Author:(Aguiar-Curry) – As Amended Ver:March 9, 2026
SUBJECT: Drug formularies.
SUMMARY: Prohibits a health plan or health insurer that provides prescription drug benefits and maintains one or more drug formularies from making changes to a formulary during a plan or policy year, except in specified circumstances. Specifically, this bill:
- Prohibits a health plan or insurer that provides prescription drug benefits and maintains one or more drug formularies from making changes to a formulary during a plan year, including removing a drug from a formulary, moving a drug to a higher cost tier, or imposing new utilization management requirements on a drug.
- Provides exemptions to allow a health plan or insurer to make changes to a formulary for any of the following reasons:
- To add a newly approved drug. Requires, if a generic drug is newly approved, the cost sharing for the newly approved generic drug to be lower than the brand name drug, but brand name drug coverage to not be removed until the end of the plan year;
- To remove a drug due to safety concerns from the United States Food and Drug Administration (FDA);
- To move a specified drug to a lower formulary tier or otherwise modify its formulary placement in a manner that reduces enrollee cost sharing; or,
- To remove utilization management or prior authorization requirements for a covered drug.
- Requires a health plan, insurer, or their pharmacy benefit manager (PBM) to report any changes made to a formulary during a plan year to the Department of Managed Health Care (DMHC) or California Department of Insurance (CDI) within 30 days of the change being made.
- Requires a health plan or insurer to authorize appeals for coverage denials based on formulary changes through its existing internal and external appeals processes.
- Allows DMHC and CDI to impose an administrative penalty for a violation of this section of not less than five hundred dollars ($500) per 1,000 enrollees and up to five thousand dollars ($5,000) per 1,000 enrollees.
- Requires DMHC and CDI, when assessing administrative penalties, to determine the appropriate penalty amount for each violation based on one or more factors as applicable.
- Requires, beginning January 1, 2030, and every five years thereafter, the penalty amounts specified in 5) above to be adjusted based on the average rate of change in premium rates for the individual and small group markets, and weighted by enrollment, since the previous adjustment.
- Requires penalties levied under this bill to be paid by the plan and not be paid by the provider, subscriber, or enrollee.
- Permits DMHC and CDI to conduct audits that relate to this bill and are not based on an enrollee’s complaint.
EXISTING LAW:
- Establishes DMHC to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and CDI to regulate health insurers. [Health and Safety Code (HSC) § 1340, et seq., and Insurance Code (INS) § 106, et seq.]
- Requires every health plan and insurer that maintains one or more drug formularies to:
- Post the formulary or formularies for each product offered on their website in a manner that is accessible and searchable by potential and current enrollees or insureds, providers, the general public, DMHC and CDI, and federal agencies as required by federal law or regulations;
- Update the formularies posted pursuant to a) with any change to those formularies on a monthly basis; and,
- No later than six months after the date that a standard formulary template is developed under 3) below, use that template to display the formulary or formularies for each product offered by the insurer. [HSC § 1367.205 and INS § 10123.192]
- Requires DMHC and CDI, by January 1, 2017, to jointly, and with input from interested parties from at least one public meeting, develop a standard formulary template. In developing the template, requires DMHC and CDI to take into consideration existing requirements for reporting of formulary information established by the federal Centers for Medicare and Medicaid Services. Requires DMHC and CDI, to the extent feasible, in developing the template to evaluate a way to include on the template cost-sharing information for drugs subject to coinsurance. [Ibid.]
- Requires the standard formulary template in 3) above to include a notification that the presence of a drug on the insurer’s formulary does not guarantee that an insured will be prescribed that drug by his or her prescribing provider for a particular medical condition. Requires the standard formulary template to do all of the following:
- Include information on cost-sharing tiers and utilization controls, including prior authorization or step therapy requirements, for each drug covered by the product;
- Indicate any drugs on the formulary that are preferred over other drugs on the formulary;
- Include information to educate insureds about the differences between drugs administered or provided under a health insurer’s medical benefit and drugs prescribed under a health insurer’s prescription drug benefit and about how to obtain coverage information about drugs that are not covered under the health insurer’s prescription drug benefit;
- Include information to educate insureds that health insurers that provide prescription drug benefits are required to have a method for insureds to obtain prescription drugs not listed in the health insurer’s drug formulary under existing law;
- Include information on which medications are covered, including both generic and brand name; and,
- Include information on what tier of the health insurer’s drug formulary each medication is in. [Ibid.]
- Defines “formulary” as the complete list of drugs preferred for use and eligible for coverage under a health care service plan product and includes the drugs covered under the pharmacy benefit of the product. [Ibid.]
- Prohibits a health plan health, on or after July 1, 1999, from limiting or excluding coverage for a drug for an enrollee if the drug previously had been approved for coverage by the plan for a medical condition of the enrollee and the plan’s prescribing provider continues to prescribe the drug for the medical condition, provided that the drug is appropriately prescribed and is considered safe and effective for treating the enrollee’s medical condition. Exempts drugs that are prescribed for a use that is different from the use for which that drug has been approved for marketing by the FDA. [HSC § 1367.22]
- Requires every health plan that provides prescription drug benefits to maintain an expeditious process by which prescribing providers may obtain authorization for a medically necessary nonformulary prescription drug. Requires, on or before July 1, 1999, every health plan that provides prescription drug benefits to file with DMHC a description of its process, including timelines, for responding to authorization requests for nonformulary drugs. Requires any changes to this process to be filed with DMHC. Requires each plan to provide a written description of its most current process, including timelines, to its prescribing providers. [HSC § 1367.24]
- Requires every health plan that provides prescription drug benefits and maintains one or more drug formularies to provide to members of the public, upon request, a copy of the most current list of prescription drugs on the formulary of the plan by major therapeutic category, with an indication of whether any drugs on the list are preferred over other listed drugs. Requires the health plan, if it maintains more than one formulary, to notify the requester that a choice of formulary lists is available. [HSC § 1367.20]
- Allows health plans to require step therapy if there is more than one clinically appropriate drug, including requiring an enrollee to try an AB-rated generic equivalent, biosimilar, or interchangeable biological product before providing coverage for the equivalent branded prescription drug. Patients can request an exception. [HSC § 1367.206]
- Requires health plans to cover at least one FDA-approved medication in several categories of opioid use disorder treatment without step therapy, prior authorization, or utilization review, and allows for these to be AB-rated generic equivalents, biosimilars, or interchangeable biological products. [HSC § 1342.75]
- Establishes the Pharmacy Law which provides for the licensure and regulation of pharmacies, pharmacists, and dangerous drug or device wholesalers, and establishes the Board of Pharmacy (Board) to enforce the Pharmacy Law. [Business and Professions Code (BPC) § 4000, et seq.]
- Authorizes a pharmacist filling a prescription for a drug product to select a different form of medication with the same active chemical ingredients of equivalent strength and duration of therapy as the prescribed drug product when the change will improve the ability of the patient to comply with the prescribed drug therapy, unless the prescriber indicates either orally or in their own handwriting, “Do not substitute” or words of similar meaning. Authorizes a prescriber to check a box on a prescription marked “Do not substitute” if the prescriber personally initials the box or checkmark. Specifies that selection of a different form of medication is within the discretion of the pharmacist and that they assume the same responsibility for selecting the dispensed drug product as would be incurred in filling a prescription for a drug product using the prescribed form of medication. Specifies that there is no liability on the prescriber for an act or omission by a pharmacist in selecting, preparing, or dispensing a drug product pursuant to this authority. In the event of substitution, requires the patient to be informed that a different form of medication is used and requires the prescription label to include the name of the dispensed drug product. Prohibits substitution between long-acting and short-acting forms of a medication with the same chemical ingredients or between one drug product and two or more drug products with the same chemical ingredients. [BPC § 4052.5]
- Further authorizes a pharmacist, when filling a prescription for a drug product prescribed by its trade brand name, to select another drug product with the same active chemical ingredients of the same strength, quantity, and dosage form, and of the same generic drug name as determined by the United States Adopted Names (USAN) and accepted by the FDA, of those drug products having the same active chemical ingredients. Outlines the same “Do not substitute” specifications, pharmacist discretion specifications, prescriber liability specifications, patient communication specifications, and prescription label specifications in 12) above. Prohibits a pharmacist from substituting unless the drug product the pharmacist selects costs the patient less than the prescribed drug product. Clarifies that cost includes any professional fee charged by the pharmacist. Specifies that these requirements apply to all prescriptions, including those presented by or on behalf of persons receiving assistance from the federal government or pursuant to the California Medical Assistance Program. [BPC § 4073]
- Authorizes a pharmacist filling a prescription for a prescribed biological product (as defined by federal law) to select an alternative biological product if the alternative biological product is interchangeable and if the prescriber does not indicate “Do not substitute” or words of similar meaning. Requires, within five days following the dispensing of a biological product, a dispensing pharmacist or their designee to make an entry of the specific biological product provided to the patient, including the name of the biological product and the manufacturer. Requires an entry that can be electronically accessed by the prescriber through various electronic records systems and specifies that entering the information into an electronic records system is presumed to provide notice to the prescriber. In the event a pharmacist does not have access to any of the various electronic records systems, authorizes the pharmacist or their designee to communicate the name of the biological product via fax, telephone, electronic transmission, or other means but the communication is not required if there is no FDA approved interchangeable biological product or if the refill is not changed from the product dispensed on the prior filling. Outlines the same “Do not substitute” specifications, pharmacist discretion specifications, prescriber liability specifications, patient communication specifications, and prescription label specifications in 12) above. Outlines the same cost specifications in 13) above. [BPC § 4073.5]
FISCAL EFFECT: Unknown. This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill prohibits health plans and PBMs from changing prescription drug coverage midyear, protecting patients from unexpected costs and treatment disruptions. The author states that this bill ensures Californians may continue needed medications, especially for chronic or serious conditions, without interruption. The author continues that this bill also brings greater clarity and predictability to coverage, helping patients plan and budget for care. The author concludes that by safeguarding access to essential medications, this bill supports continuity of treatment, reduces administrative burdens on providers, and strengthens patient protections.
- BACKGROUND. Health plans have a list of drugs they have already approved for coverage. This list is called a formulary. Formularies are a tool used by plans to adapt to the evolving landscape of pharmacy products. With the rise of high-cost and specialty drugs, formulary management can be leveraged as a strategy to manage costs for the plan and enrollee while optimizing enrollee access to a range of prescription drugs.
- Rising Prescription Drug Spending and SB 17 Report. In 2021, the U.S. spent an average of $691 more per person on retail pharmaceuticals, over-the-counter drugs, and medical equipment than comparable countries. From 2020 to 2023, national retail prescription drug spending rates increased by 8.6%, following a 3.3% increase in average annual growth the decade before, outpacing spending growth on hospitals or physicians and clinics. When drug prices increase, these costs get passed to employers and health plan enrollees via increased premiums. The 2025 California Health Benefits Survey reports that 36% of large California companies (over 200 employees) report that prescription drug prices contributed “a great deal” to higher premiums, including 63% of companies with 5,000 or more workers. SB 17 (Hernandez), Chapter 603, Statutes of 2017 requires health plans in the commercial market to annually report their prescription drug costs to the DMHC. This report looks at the impact of the cost of prescription drugs on health plan premiums and compares this data across the reporting years. The cost of prescription drugs continues to impact the affordability of health care overall, with health plans paying about $14.9 billion for prescription drugs in 2024. Prescription drug costs have increased at a higher rate compared to medical expenses and health plan premiums. Total prescription drug costs increased by 9.5% in 2024, whereas total medical expenses increased by 6.9% and health plan premiums increased by 8% from 2023 to 2024. Specialty drugs and brand name drugs are primary drivers of the increase in total prescription drug-cost spending. Brand name drugs account for only 9.4% of all prescriptions dispensed but accounted for 25.2% of total annual spending on prescription drugs. In contrast, generic drugs accounted for 88.8% of all prescriptions but only 11.8% of the total annual spending on prescription drugs. According to the DMHC, health plans paid almost $1.3 billion more on prescription drugs in 2024 than in 2023. Since 2017, total prescription drug costs paid by health plans increased by $6.2 billion or 72%.
- Current Avenues to Promote Adoption of Lower-Cost Drugs. Given that prescription drugs, particularly brand name and specialty drugs, are a leading driver in skyrocketing health care costs – legislators, consumer advocates, and health plans have been pushing policy reforms to increase the adoption of generics, biosimilars, and other lower-cost drugs. Under existing state law, when a drug product is prescribed by its brand name, a pharmacist may select an equivalent drug product with the same active ingredient, strength, and dosage form, unless the prescribing provider indicates “Do not substitute.” This authority applies at the time of dispensing and permits the pharmacist, in their professional discretion, to select among therapeutically equivalent products, including substituting a generic drug for a brand-name drug, and interchangeable biosimilar for a brand-name biologic, or dispensing products from different manufacturers over time, provided that the substituted product complies with applicable equivalence, labeling, and cost requirements. Pharmacies routinely dispense an FDA-approved equivalent product that is covered or preferred by a patient’s health plan, which can result in patients receiving different generic versions across refills. The pharmacist is dispensing a therapeutically equivalent drug product rather than altering the prescription itself. SB 1094 (Weber Pierson) of this year is proposing to expand this law to allow pharmacists to substitute brand name biologics for any biosimilar, not just those deemed interchangeable.
While enrollees choose a plan for the plan year, changes in what is covered, health plan contracts, new prescription drugs and uses, and more can happen at any time of the year. Health plans and PBMs negotiate their drug contracts and formularies throughout the year, not only at the beginning of the plan year. Although some formulary changes may be disruptive for patients and providers, many of these changes mean there is a more affordable drug available, a different use for a drug, or a new generic or biosimilar has come to market. To allow plans to maintain formulary negotiating flexibility while ensuring patient continuity of care, existing law prohibits health plans from limiting or excluding coverage for a drug for an enrollee if the drug previously had been approved for coverage by the plan for their medical condition. Existing law also requires health plans to maintain a process for providers to request authorization to prescribe a medically necessary prescription drug that isn’t on their formulary.
- SUPPORT. The California Academy of Family Physicians (CAFP) is sponsoring this bill, stating that patients choose health plans during open enrollment partly based on which medications are covered and the costs associated with those drugs. CAFP continues that mid-year formulary changes, such as removing drugs, increasing cost-sharing, or adding new prior authorization or step therapy requirements, can leave patients without access to the treatments they depend on. CAFP argues that these changes are often driven by financial considerations rather than clinical need and can result in medication disruptions, worsening health outcomes, and increased health care utilization. CAFP notes that for physicians, these shifts also create a significant administrative burden, requiring time-consuming prior authorization requests for treatments that were already deemed medically necessary, ultimately taking time away from patient care. CAFP continues that this bill provides an important safeguard by requiring health plans to honor the coverage and cost-sharing terms in place at the start of the plan year. CAFP concludes that by preventing mid-year formulary changes while allowing patient-centered exceptions, this bill promotes continuity of care, protects patients from unexpected costs, and reduces unnecessary administrative hurdles for physicians.
- SUPPORT IF AMENDED. Health Access supports this bill if amended. Health Access supports the intent of the bill to ensure continuity of care for consumers when there are changes to the formulary during the health plan, however they want to ensure that consumers are able to benefit from cost savings that health plans are able to secure mid-year as soon as possible. Health Access is requesting amendments that would narrow the prohibition on changes during the year, allow for further exceptions to the prohibition and other changes that would ensure more affordable and the best quality care for consumers. Health Access notes that existing law allows for substitutions for the generic for the brand name drug to ensure cost-savings for consumers. When a generic comes to market, the pharmaceutical company typically increases the price of the brand name drug and marketing to consumers and prescribers for the product one to two years leading up to it. That is why Health Access requests removing the requirement to keep the brand name drug on the formulary for the rest of the plan year. Health Access notes that this aligns with existing law that prioritizes ensuring consumers are prescribed the generic of the drug that is more affordable. With the same goal, Health Access proposes a similar exception for biosimilars and interchangeable biologics that would result in lower cost-sharing for the consumer. Health Access further requests amendments removing the prohibition on removals of drugs from the formulary and new utilization management during the plan year to ensure that consumers see the benefits of health plan negotiations for more affordable drugs for the formulary or research changes on prescription drugs. Health Access provides an example of changes that benefit consumers is if a drug is found to treat a condition different than manufactured for. Health Access concludes that their amendments would ensure that changes in the formulary that would benefit consumers would still be allowed and further continuity of care protections.
- OPPOSITION. The California Association of Health Plans (CAHP) and Association of California Life and Health Insurance Companies (ACLHIC) are strongly opposed to this bill, stating that it would fundamentally undermine their ability to ensure patient safety, respond to emerging clinical data, and manage the skyrocketing costs of prescription drugs. CAHP and ACLHIC continue that by "freezing" formularies mid-year, this bill inadvertently protects pharmaceutical manufacturer profits at the expense of California consumers and employers. CAHP and ACLHIC note that this bill restricts a plan’s ability to act swiftly when new clinical evidence emerges. While the bill provides limited exceptions for FDA mandated removals, it ignores the reality that health plans and insurers are often the first to identify safety issues through real-world data. CAHP and ACLHIC continue that the bill’s current language restricts the adoption of lower-cost alternatives, which is the primary driver of prescription drug savings for consumers. CAHP and ACLHIC note that "egregious" administrative penalties and audit authority in this bill far exceed any reasonable standard. CAHP and ACLHIC are deeply concerned by the provision that would make a willful violation a crime, creating a state-mandated local program for what are essentially clinical and fiscal management decisions. CAHP and ACLHIC conclude that this bill would freeze California’s health care system in a way that prevents health plans and insurers from adopting evidence-based treatment.
The Pharmaceutical Care Management Association (PCMA) is also opposed to this bill, because it would limit a PBM’s ability to manage drug formularies, one of the most important tools for lowering prescription drug costs by holding drug manufacturers accountable. PCMA continues that big pharma regularly increases list prices, often drastically and without justification or advance notice to plans. PCMA argues that PBM tools, including formulary management, are used to protect employers and patients from these increases. PCMA states that the National Academy of Science, Engineering and Technology notes that formulary controls help keep premiums low, formulary management best practices can reduce costs by roughly 10% compared to an unmanaged benefit. PCMA concludes that as written, this bill will only encourage drug manufacturers to increase drug prices mid-year and remove incentives to offer discounts, knowing a plan must cover a drug, regardless of a more cost-efficient alternative becoming available.
- RELATED LEGISLATION. SB 1094 (Weber Pierson) would authorize a pharmacist to select an alternative biological product for a prescribed biological product if it is a biosimilar. Would authorize health plans and insurers to require enrollees to try a therapeutically equivalent generic, biosimilar, or interchangeable biological product if the prescriber has not indicated “Do not substitute” and when the generics or biosimilars are covered by the health plan or insurer and available to the enrollee at the same or lower cost. AB 1094 is currently pending in the Senate Health Committee.
- PREVIOUS LEGISLATION.
- SB 671 (Hill), Chapter 545, Statutes of 2015 authorizes a pharmacist to substitute an alternative biological product when filling a prescription for a prescribed biological product if the alternative biological product is designated as interchangeable with the reference product, among other conditions, and communication is provided to the patient and physician that a substitution was made. It also requires the Board of Pharmacy to maintain a link on its internet website to the list of biological products recognized as interchangeable by the FDA.
- SB 598 (Hill) of 2013 would have authorized pharmacists to substitute a biosimilar for a biologic under specified circumstances, including a requirement that notification of the substitution be provided, and defined “biological product,” “biosimilar,” and “interchangeable.” SB 598 was vetoed by Governor Brown who noted that “CalPERS and other large purchasers warn that the requirement itself would cast doubt on the safety and desirability of more cost-effective alternatives to biologics….The FDA, which has jurisdiction for approving all drugs, has not yet determined what standards will be required for biosimilars to meet the higher threshold for “interchangeability.”
- AB 1139 (Lowenthal) of 2013 would have authorized a pharmacist to substitute a biosimilar for a biological product if the product is deemed by the FDA to be interchangeable with the biological product. AB 1139 was held in the Assembly Business and Professions Committee.
- PROPOSED AMENDMENTS. To address concerns on the proposed formulary limitations contributing to the rising cost of drugs and care while balancing the need to ensure access to medically necessary care for consumers, the author and committee have agreed to amendments to do the following:
- Remove prohibition on changes in utilization management and removal of prescription drugs from the formulary during the plan or policy year;
- Remove the requirement that a brand name drug remain on the formulary for the entirety of a plan or policy year;
- Ensure formulary change exemptions for generic additions also apply to biosimilars;
- Ensure health plans and insurers can add any drug, not just newly approved drugs, to their formulary. Clarify that if a drug is replacing a previously covered drug in the same drug class during the plan year that it must result in the same or lower cost sharing;
- Clarify that existing law allows consumers to remain on a drug that was previously covered by DMHC regulated plans, provided that the drug is appropriately prescribed and considered safe and effective for treating the enrollee’s medical condition;
- Require a plan or insurer to notify a consumer and the prescribing provider if they plan to implement a formulary change that will require the consumer to change to a different drug in the same drug class during the plan year no less than 90 days before the formulary change is implemented. Requires the notification for DMHC regulated plans to include information on continuity of previously covered drugs as noted in e) above;
- Update existing law requiring plans to maintain an expeditious process for requests to cover nonformulary drugs. Require the expeditious process to follow the same timelines as prior authorization requests. Require a plan to provide 90 days of transitional coverage for a requested drug, if the timelines are not met;
- Require DMHC to leverage existing data and authority to collect data on enrollee requests for coverage of nonformulary drugs, any denials/appeals of those requests, and outcomes of disputes; and,
- Permit DMHC and CDI to investigate and take enforcement against noncompliance with this bill, require notification and the opportunity for a hearing prior to assessing penalties.
REGISTERED SUPPORT / OPPOSITION:
Support
California Academy of Family Physicians (sponsor)
Association for Clinical Oncology
California Chronic Care Coalition
California Life Sciences Association
Crohn’s and Colitis Foundation
National Health Law Program
Opposition
Association of California Life & Health Insurance Companies
California Association of Health Plans
Pharmaceutical Care Management Association
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):